Aadi Bioscience, Inc. (NASDAQ:AADI) Position Lowered by Jane Street Group LLC

Jane Street Group LLC lessened its holdings in Aadi Bioscience, Inc. (NASDAQ:AADI) by 80.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,989 shares of the company’s stock after selling 108,245 shares during the quarter. Jane Street Group LLC owned approximately 0.11% of Aadi Bioscience worth $54,000 at the end of the most recent quarter.

Separately, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Aadi Bioscience during the second quarter worth about $37,000. 52.08% of the stock is owned by institutional investors and hedge funds.

Aadi Bioscience Stock Performance

Aadi Bioscience stock opened at $3.24 on Thursday. The company has a 50-day simple moving average of $2.65 and a 200-day simple moving average of $2.05. The firm has a market capitalization of $79.86 million, a P/E ratio of -1.42 and a beta of 0.65. Aadi Bioscience, Inc. has a one year low of $1.21 and a one year high of $3.81.

Aadi Bioscience (NASDAQ:AADI) last announced its earnings results on Wednesday, November 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.46). The firm had revenue of $7.21 million during the quarter, compared to analyst estimates of $6.55 million. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. During the same quarter in the prior year, the firm posted ($0.60) EPS. As a group, sell-side analysts forecast that Aadi Bioscience, Inc. will post -1.78 earnings per share for the current year.

Aadi Bioscience Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.